- Q1 2024 Seres Therapeutics Inc Earnings Call TranscriptMay 08, 2024$0.7494 (-32.49%)Earnings
- Q4 2023 Seres Therapeutics Inc Earnings Call TranscriptMar 05, 2024$1.06 (-7.02%)Earnings
- Seres Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Q3 2023 Seres Therapeutics Inc Earnings Call TranscriptNov 02, 2023$0.9324 (-35.25%)Earnings
- Seres Therapeutics Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- Seres Therapeutics Inc at Canaccord Genuity Growth Conference TranscriptAug 09, 2023
- Q2 2023 Seres Therapeutics Inc Earnings Call TranscriptAug 08, 2023$4.29 (-6.94%)Earnings
- Seres Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- Seres Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Q1 2023 Seres Therapeutics Inc Earnings Call TranscriptMay 09, 2023$5.57 (+0.18%)Earnings
- Seres Therapeutics Inc To Discuss SER-109 Approval Call TranscriptApr 27, 2023
- Q4 2022 Seres Therapeutics Inc Earnings Call TranscriptMar 07, 2023$5.4 (-1.64%)Earnings
- Seres Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 12, 2023
- Seres Therapeutics Inc To Discuss Ser-109 Commercial Strategy Call TranscriptDec 08, 2022
- Q3 2022 Seres Therapeutics Inc Earnings Call TranscriptNov 02, 2022$8.19 (-9.50%)Earnings
- Q2 2022 Seres Therapeutics Inc Earnings Call TranscriptAug 03, 2022$4.45 (+8.54%)Earnings
- Seres Therapeutics Inc To Discuss 109 ECOSPOR IV Study Results Call TranscriptJun 07, 2022
- Q1 2022 Seres Therapeutics Inc Earnings Call TranscriptMay 04, 2022$4.72 (-2.48%)Earnings
- Q4 2021 Seres Therapeutics Inc Earnings Call TranscriptMar 01, 2022$7.4 (-7.56%)Earnings
- Seres Therapeutics Inc To Highlight Opportunities For Microbiome Therapeutics In Infection Protection Call TranscriptJan 31, 2022
- Seres Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Q3 2021 Seres Therapeutics Inc Earnings Call TranscriptNov 10, 2021$8.27 (+20.38%)Earnings
- Q2 2021 Seres Therapeutics Inc Earnings Call TranscriptAug 03, 2021$6.96 (-1.00%)Earnings
- Seres Therapeutics Inc To Discuss Topline Results From The Phase 2b ECO-RESET Study Evaluating SER-287 In Patients With Mild-To-Moderate Ulcerative Colitis Call TranscriptJul 22, 2021
- Seres Therapeutics Inc SER-109 Co-Commercialization License Agreement Call TranscriptJul 01, 2021
- Seres Therapeutics Inc SER-287 Clinical Data Update Call TranscriptJun 21, 2021
- Seres Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 08, 2021
- Q1 2021 Seres Therapeutics Inc Earnings Call TranscriptMay 04, 2021$21.48 (+5.55%)Earnings
- Q4 2020 Seres Therapeutics Inc Earnings Call TranscriptMar 02, 2021$19.62 (-4.85%)Earnings
- Seres Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Q3 2020 Seres Therapeutics Inc Earnings Call TranscriptNov 09, 2020$33.24 (-3.90%)Earnings
- Seres Therapeutics, Inc. - Special Call TranscriptAug 10, 2020
- Seres Therapeutics Inc Annual Shareholders Meeting TranscriptJun 18, 2020
- Seres Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 09, 2020
- Seres Therapeutics, Inc. - Special Call TranscriptMay 27, 2020
- Q1 2020 Seres Therapeutics Inc Earnings Call TranscriptMay 07, 2020$4.27 (+12.37%)Earnings
- Q4 2019 Seres Therapeutics Inc Earnings Call TranscriptMar 02, 2020$3.23 (+2.87%)Earnings
- Q3 2019 Seres Therapeutics Inc Earnings Call TranscriptNov 05, 2019$4.06 (+6.84%)Earnings
- Q2 2019 Seres Therapeutics Inc Earnings Call TranscriptAug 06, 2019$2.29 (-6.15%)Earnings
- Q1 2019 Seres Therapeutics Inc Earnings Call TranscriptMay 02, 2019$5.35 (-12.44%)Earnings
- Q4 2018 Seres Therapeutics Inc Earnings Call TranscriptMar 06, 2019$6.12 (-3.62%)Earnings
Seres Therapeutics Inc at JPMorgan Healthcare Conference Transcript
&-
Welcome everyone to the 42nd annual JP Morgan Healthcare Conference. My name is Tess Romero, and I am one of the senior biotech analysts here at JPMorgan. Our next presenting company is Seres Therapeutics and presenting on behalf of the company. We have CEO Eric Shaff. Eric?
Well, thank you, Tess, and thanks to JPMorgan for having us here today. It's great to be in person with you this morning at JPMorgan and have the opportunity to connect. And together, I'm joined with my team, David Terri, Matt, and Rob, and we're thrilled to be here to talk about Seres and answer your questions following a short presentation. So I will be making forward-looking statements in this presentation. So as usual, I encourage you to review our Safe Harbor statement and risk factors in our last 10-Q.
So excited to start this morning with a discussion around two key updates that we are pleased to share. The first is preliminary Q4 commercial results
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)